Trevi Therapeutics, Inc. Profile Avatar - Palmy Investing

Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation…

Biotechnology
US, New Haven [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Trevi Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of TRVI's Analysis
CIK: 1563880 CUSIP: 89532M101 ISIN: US89532M1018 LEI: - UEI: -
Secondary Listings
TRVI has no secondary listings inside our databases.